FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

NC 143 Family Holdings, LP

2. Date of Event Requiring Statement (MM/DD/YYYY)
11/17/2016 

3. Issuer Name and Ticker or Trading Symbol

Fuse Medical, Inc. [FZMD]

(Last)        (First)        (Middle)

1565 N. CENTRAL EXPRESSWAY, SUITE 200

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                            ___ X ___ 10% Owner
_____ Officer (give title below)          _____ Other (specify below)

(Street)

RICHARDSON, TX 75080       

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed (MM/DD/YYYY)

1/13/2017 

6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4) 		2. Amount of Securities Beneficially Owned
(Instr. 4) 		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) 		4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4) 		2. Date Exercisable and Expiration Date
(MM/DD/YYYY) 		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) 		4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) 		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Amended and Restated Promissory Note   1/16/2017     (1) Common Stock   656678   (2) $0.08   D   (3)  
Promissory Note   1/16/2017     (4) Common Stock   640239   (5) $0.08   D   (3)  

Explanation of Responses:
(1)  The Amended and Restated Promissory Note, dated October 19, 2016, made by the Issuer and payable to the order of NC 143 Family Holdings, LP, a Texas limited partnership ("NC 143"), in the principal amount of $50,000 ("NC 143 Note #1") became payable upon demand on December 19, 2016, and will be convertible into shares of common stock of the Issuer on or after January 16, 2017. NC 143 Note #1 does not provide for a stated expiration date.
(2)  On or after January 16, 2017, NC 143 will have the right to convert all or any portion of the then unpaid principal and interest balance of NC 143 Note #1 into shares of common stock of the Issuer at a conversion price of $0.08 per share. The number of shares reported in box 3 is based on the application of such conversion rate to the amount of principal and interest that will be outstanding on January 16, 2017, if NC 143 Note #1 remains outstanding on such date.
(3)  These securities are directly owned by NC 143, however both the Medtech Family Trust dated October 1, 2014 ("Medtech"), and NC 143 Family Holdings GP LLC ("GP") indirectly own the reported securities. Medtech is the sole manager of the GP, and the GP is the sole general partner of NC 143. Accordingly, both Medtech and the GP indirectly beneficially own the reported securities. This Form 4 is filed jointly by NC 143, Medtech, and the GP.
(4)  The Promissory Note, dated October 19, 2016, made by the Issuer and payable to the order of NC 143 in the principal amount of $50,000 ("NC 143 Note #2") became payable upon demand on December 19, 2016 and will be convertible into shares of common stock of the Issuer on or after January 16, 2017. NC 143 Note #2 does not provide for a stated expiration date.
(5)  On or after January 16, 2017, NC 143 will have the right to convert all or any portion of the then unpaid principal and interest balance of NC 143 Note #2 into shares of common stock of the Issuer at a conversion price of $0.08 per share. The number of shares reported in box 3 is based on the application of such conversion rate to the amount of principal and interest that will be outstanding on January 16, 2017, if NC 143 Note #2 remains outstanding on such date.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
NC 143 Family Holdings, LP
1565 N. CENTRAL EXPRESSWAY, SUITE 200
RICHARDSON, TX 75080
X

Medtech Family Trust
1565 NORTH CENTRAL EXPWY, SUITE 200
RICHARDSON, TX 75080
X

NC 143 Family Holdings GP LLC
1565 NORTH CENTRAL EXPWY, SUITE 200
RICHARDSON, TX 75080
X


Signatures
/s/ Mark W. Brooks 1/26/2018
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Grafico Azioni Fuse Medical (PK) (USOTC:FZMD)
Storico
Da Apr 2024 a Mag 2024 Clicca qui per i Grafici di Fuse Medical (PK)
Grafico Azioni Fuse Medical (PK) (USOTC:FZMD)
Storico
Da Mag 2023 a Mag 2024 Clicca qui per i Grafici di Fuse Medical (PK)